May 18, 2020 Real-World Data Analysis Published in the Journal of Urology Explores Frequency of Late Luteinizing Hormone-Releasing Hormone Agonist (LHRH) Dosing and Impact on Testosterone Suppression in Patients with Prostate Cancer
August 2, 2019 Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology
May 14, 2017 Data From Tolmar Pharmaceuticals on ELIGARD Demonstrate Serum Leuprolide Levels Required to Maintain Stable, Long-Term Testosterone Suppression Across All Doses Serum Level of Leuprolide Acetate Required to Maintain Low T Established
May 8, 2017 Tolmar, Inventor and Developer of ELIGARD® (leuprolide acetate for injectable suspension), Announces Plans to Expand Manufacturing Facilities in Colorado
May 6, 2016 Tolmar Pharmaceuticals Announces That FDA Approval Has Been Received For ELIGARD® (leuprolide acetate for injectable suspension) Storage at Room Temperature For up to 8 Weeks
May 18, 2015 Data From Tolmar Pharmaceuticals Demonstrate ELIGARD® (leuprolide acetate for injectable suspension) Consistently Suppresses Serum Testosterone Levels in Patients With Advanced Prostate Cancer
